Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Journal of Orthopaedic Surgery and Research

Fig. 1

From: Dysregulation of miR-106a-5p/PTEN axis associated with progression and diagnostic of postmenopausal osteoporosis

Fig. 1

Expression levels and diagnostic value of miR-106a-5p. (A) Expression levels of miR-106a-5p in control (n = 112) and PMOP (n = 108) groups. (B) Diagnostic value of miR-106a-5p as assessed by ROC curve. (C) Abundance of miR-106a-5p in FAC-treated hFOB1.19 cells (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. Control. FAC, ferric ammonium citrate; PMOP, postmenopausal osteoporosis; ROC, receiver operating characteristic

Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X